Quick Answer
Vaxcyte, Inc. reported Cash And Cash Equivalents At Carrying Value of $173.96 million for the year ending 2025.
- Vaxcyte, Inc. showed a decrease of -55.2% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Vaxcyte, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $410.05 million | Q3 2020: $397.05 million | Q1 2021: $198.94 million | Q2 2021: $151.00 million | Q3 2021: $112.04 million | Q1 2022: $201.74 million | Q2 2022: $238.17 million | Q3 2022: $278.40 million | Q1 2023: $380.45 million | Q2 2023: $531.03 million | Q3 2023: $545.13 million | Q1 2024: $611.51 million | Q2 2024: $518.67 million | Q3 2024: $1.05 billion | Q1 2025: $346.85 million | Q2 2025: $306.74 million | Q3 2025: $281.08 million.
- Over the full 7 years of available data (2019 to 2025), Vaxcyte, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 195.0%.
- Historical annual values: Fiscal year 2025: $173.96 million | Fiscal year 2024: $387.88 million | Fiscal year 2023: $397.45 million | Fiscal year 2022: $834.66 million | Fiscal year 2021: $68.99 million | Fiscal year 2020: $386.20 million | Fiscal year 2019: $58.98 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: